PDF(Pubmed)
Abstract：
UNASSIGNED: Previous studies have revealed that Galectin-9 (Gal-9) acts as an apoptosis modulator in autoimmunity and rheumatic inflammation. In the present study, we investigated the potential role of Gal-9 as a biomarker in patients with rheumatoid arthritis (RA), especially as an indicator of functional limitations and radiographic joint damage.
UNASSIGNED: A total of 146 patients with RA and 52 age- and sex-matched healthy controls were included in this study. Clinical data including disease activity, physical function, and radiographic joint damage were assessed. Functional limitation was defined as the Stanford Health Assessment Questionnaire (HAQ) disability index >1. Subjects with joint erosion >0 or joint space narrowing >0 were considered to have radiographic joint damage. Serum Gal-9 levels were detected by an enzyme-linked immunosorbent assay. Univariate and multivariate logistic regression analysis were used to evaluate the association between Gal-9 and high disease activity and functional limitations, and a prediction model was established to construct predictive nomograms.
UNASSIGNED: Serum levels of Gal-9 were significantly increased in patients with RA compared to those in healthy controls (median 13.1 ng/mL vs. 7.6 ng/mL). Patients with RA who were older (>65 years), had a longer disease duration (>5 years), longer morning stiffness (>60mins), elevated serum erythrocyte sedimentation rate and C-reactive protein, and difficult-to-treat RA had significantly higher Gal-9 levels than those in the corresponding control subgroups (all p <0.05). Patients with RA were divided into two subgroups according to the cut-off value of Gal-9 of 11.6 ng/mL. Patients with RA with Gal-9 >11.6 ng/mL had a significantly higher core clinical disease activity index, HAQ scores, Sharp/van der Heijde modified Sharp scores, as well as a higher percentage of advanced joint damage (all p<0.05) than patients with Gal-9 ≤11.6 ng/mL. Accordingly, patients with RA presenting either functional limitations or radiographic joint damage had significantly higher serum Gal-9 levels than those without (both p <0.05). Furthermore, multivariate logistic regression analysis showed that a serum level of Gal-9 >11.6 ng/mL was an independent risk factor for high disease activity (OR=3.138, 95% CI 1.150-8.567, p=0.026) and presence of functional limitations (OR=2.455, 95% CI 1.017-5.926, p=0.046), respectively.
UNASSIGNED: Gal-9 could be considered as a potential indicator in patients with RA, especially with respect to functional limitations and joint damage.
UNASSIGNED: A total of 146 patients with RA and 52 age- and sex-matched healthy controls were included in this study. Clinical data including disease activity, physical function, and radiographic joint damage were assessed. Functional limitation was defined as the Stanford Health Assessment Questionnaire (HAQ) disability index >1. Subjects with joint erosion >0 or joint space narrowing >0 were considered to have radiographic joint damage. Serum Gal-9 levels were detected by an enzyme-linked immunosorbent assay. Univariate and multivariate logistic regression analysis were used to evaluate the association between Gal-9 and high disease activity and functional limitations, and a prediction model was established to construct predictive nomograms.
UNASSIGNED: Serum levels of Gal-9 were significantly increased in patients with RA compared to those in healthy controls (median 13.1 ng/mL vs. 7.6 ng/mL). Patients with RA who were older (>65 years), had a longer disease duration (>5 years), longer morning stiffness (>60mins), elevated serum erythrocyte sedimentation rate and C-reactive protein, and difficult-to-treat RA had significantly higher Gal-9 levels than those in the corresponding control subgroups (all p <0.05). Patients with RA were divided into two subgroups according to the cut-off value of Gal-9 of 11.6 ng/mL. Patients with RA with Gal-9 >11.6 ng/mL had a significantly higher core clinical disease activity index, HAQ scores, Sharp/van der Heijde modified Sharp scores, as well as a higher percentage of advanced joint damage (all p<0.05) than patients with Gal-9 ≤11.6 ng/mL. Accordingly, patients with RA presenting either functional limitations or radiographic joint damage had significantly higher serum Gal-9 levels than those without (both p <0.05). Furthermore, multivariate logistic regression analysis showed that a serum level of Gal-9 >11.6 ng/mL was an independent risk factor for high disease activity (OR=3.138, 95% CI 1.150-8.567, p=0.026) and presence of functional limitations (OR=2.455, 95% CI 1.017-5.926, p=0.046), respectively.
UNASSIGNED: Gal-9 could be considered as a potential indicator in patients with RA, especially with respect to functional limitations and joint damage.
摘要：
■先前的研究表明，半乳糖凝集素-9（Gal-9）在自身免疫和风湿性炎症中起细胞凋亡调节剂的作用。在本研究中,我们调查了Gal-9作为类风湿关节炎（RA）患者的生物标志物的潜在作用，特别是作为功能限制和射线照相关节损伤的指标。
■本研究共纳入146例RA患者和52例年龄和性别匹配的健康对照。包括疾病活动在内的临床数据，物理功能，和放射学关节损伤进行了评估。功能受限定义为斯坦福健康评估问卷（HAQ）残疾指数>1。关节侵蚀>0或关节间隙狭窄>0的受试者被认为具有影像学关节损伤。通过酶联免疫吸附试验检测血清Gal-9水平。单变量和多变量逻辑回归分析用于评估Gal-9与高疾病活动性和功能限制之间的关联。建立预测模型,构建预测列线图。
■与健康对照组相比，RA患者的Gal-9血清水平显着增加（中位数13.1ng/mL与7.6ng/mL)。年龄较大（>65岁）的RA患者，疾病持续时间较长（>5年），更长的早晨僵硬（>60分钟），升高的血清红细胞沉降率和C反应蛋白，难以治疗的RA患者的Gal-9水平明显高于相应的对照组（均p<0.05）。根据Gal-9的临界值为11.6ng/mL，将RA患者分为两个亚组。Gal-9>11.6ng/mL的RA患者的核心临床疾病活动指数明显更高，HAQ评分,夏普/范德海德修改了夏普分数，以及与Gal-9≤11.6ng/mL的患者相比，晚期关节损伤的百分比更高（均p<0.05）。因此，存在功能受限或影像学关节损伤的RA患者的血清Gal-9水平显著高于无RA患者(均P<0.05).此外，多因素logistic回归分析显示，血清Gal-9水平>11.6ng/mL是高疾病活动度（OR=3.138，95％CI1.150-8.567，p=0.026）和存在功能限制（OR=2.455，95％CI1.017-5.926，p=0.046）的独立危险因素。分别。
■Gal-9可以被认为是RA患者的潜在指标，特别是在功能限制和关节损伤方面。
■本研究共纳入146例RA患者和52例年龄和性别匹配的健康对照。包括疾病活动在内的临床数据，物理功能，和放射学关节损伤进行了评估。功能受限定义为斯坦福健康评估问卷（HAQ）残疾指数>1。关节侵蚀>0或关节间隙狭窄>0的受试者被认为具有影像学关节损伤。通过酶联免疫吸附试验检测血清Gal-9水平。单变量和多变量逻辑回归分析用于评估Gal-9与高疾病活动性和功能限制之间的关联。建立预测模型,构建预测列线图。
■与健康对照组相比，RA患者的Gal-9血清水平显着增加（中位数13.1ng/mL与7.6ng/mL)。年龄较大（>65岁）的RA患者，疾病持续时间较长（>5年），更长的早晨僵硬（>60分钟），升高的血清红细胞沉降率和C反应蛋白，难以治疗的RA患者的Gal-9水平明显高于相应的对照组（均p<0.05）。根据Gal-9的临界值为11.6ng/mL，将RA患者分为两个亚组。Gal-9>11.6ng/mL的RA患者的核心临床疾病活动指数明显更高，HAQ评分,夏普/范德海德修改了夏普分数，以及与Gal-9≤11.6ng/mL的患者相比，晚期关节损伤的百分比更高（均p<0.05）。因此，存在功能受限或影像学关节损伤的RA患者的血清Gal-9水平显著高于无RA患者(均P<0.05).此外，多因素logistic回归分析显示，血清Gal-9水平>11.6ng/mL是高疾病活动度（OR=3.138，95％CI1.150-8.567，p=0.026）和存在功能限制（OR=2.455，95％CI1.017-5.926，p=0.046）的独立危险因素。分别。
■Gal-9可以被认为是RA患者的潜在指标，特别是在功能限制和关节损伤方面。
